Diabetes in America - The Incretin Effect (5:46)

In this video, Dr Leahy describes the incretin effect and the role of native glucagon-like peptide-1 (GLP-1) in digestion and blood glucose regulation in normal physiology.

0313-00013805-1
0313-00013805-1
Play
Pause
Skip
Volume
Chapters
Transcript
References
Subtitles
Fullscreen

Diabetes in America - The Incretin Effect (5:46)

Chapters
Transcript
References

In this video, Dr Leahy describes the incretin effect and the role of native glucagon-like peptide-1 (GLP-1) in digestion and blood glucose regulation in normal physiology.

Return to overview

Transcripts

Return to overview

References

1. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced
    incretin effect in type 2 (non-insulin-dependent)
    diabetes.Diabetologia. 1986;29(1):46-52.

2. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin
    response to oral and intravenous glucose administration.
    J Clin Endocrinol Metab. 1964;24:1076-1082.

3. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors
    in the control of insulin secretion. J Clin Endocrinol Metab.
    1965;25(10):1317-1324.

4. Drucker DJ, Nauck MA. The incretin system: glucagon-like
    peptide-1 receptor agonists and dipeptidyl peptidase-4
    inhibitors in type 2 diabetes. Lancet. 2006;368(9548):
    1696-1705.

5. Chelikani PK, Haver AC, Reidelberger RD. Intravenous
    infusion of glucagon-like peptide-1 potently inhibits
    food intake, sham feeding, and gastric emptying in rats.
    Am J Physiol Regul Integr Comp Physiol. 2005:288(6):
    R1695-R1706.

6. Little TJ, Pilichiewicz AN, Russo A, et al. Effects of
    intravenous glucagon-like peptide-1 on gastric emptying
    and intragastric distribution in healthy subjects:
    relationships with postprandial glycemic and insulinemic
    responses. J Clin Endocrinol Metab. 2006;91(5):
    1916-1923.

7. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W,
    Nauck MA. Gastric emptying, glucose responses, and
    insulin secretion after liquid test meal: effects of
    exogenous glucagon-like peptide-1 (GLP-1)- (7-36)
    amide in type 2 (non-insulin dependent) diabetic patients.
    J Clin Endocrinol Metab. 1996;81:327-332.

8. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide
    1 promotes satiety and suppresses energy intake in
    humans. J Clin Invest. 1998;101(3):515-520.

9. Gutzwiller JP, Drewe J, Göke B, et al. Glucagon-like
    peptide-1 promotes satiety and reduces food intake
    in patients with diabetes mellitus type 2. Am J Physiol.
    1999;276(5, pt 2):R1541-R1544.

10. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous
      subcutaneous infusion of glucagon-like peptide 1
      lowers plasma glucose and reduces appetite in
      type 2 diabetic patients. Diabetes Care. 1999;
      22(7):1137-1143.

11. Näslund E, Gutniak M, Skogar S, Rössner S,
     Hellström PM. Glucagon-like peptide 1 increases
     the period of postprandial satiety and slows gastric
     emptying in obese men. Am J Clin Nutr. 1998;68(3):
     525-530.

12. Creutzfeldt WO, Kleine N, Willms B, Orskov C,
      Holst JJ, Nauck MA. Glucagonostatic actions and
      reduction of fasting hyperglycemia by exogenous
      glucagon-like peptide 1(7-36) amide in type 1
      diabetic patients. Diabetes Care. 1996;19(6):580-586.

13. Nauck M, Heimesaat MM, Orskov C, Holst JJ, Ebert R,
      Creutzfeldt W. Preserved incretin activity of glucagon-
      like peptide 1 [7-36 amide] but not of synthetic human
      gastric inhibitory polypeptide in patients with type-2
      diabetes mellitus. J Clin Invest. 1993;91(1):301-307.

14. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B,
     Creutzfeldt W. Normalization of fasting hyperglycaemia
     by exogenous glucagon-like peptide 1 (7-36 amide)
     in type 2 (non-insulin-dependent) diabetic patients. 
     Diabetologia. 1993;36(8):741-744.

15. Hargrove DM, Nardone NA, Persson LM, Parker JC,
     Stevenson RW. Glucose-dependent action of glucagon-
     like peptide-1 (7-37) in vivo during short- or long-term
     administration. Metabolism. 1995;44(9):1231-1237.

16. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.
      Differential effects of acute and extended infusion of
      glucagon-like peptide-1 on first- and second-phase
      insulin secretion in diabetic and nondiabetic humans.
      Diabetes Care. 2003;26(3):791-798.

17. Rachman J, Barrow BA, Levy JC, Turner RC. Near-
     normalization of diurnal glucose concentrations by
     continuous administration of glucagon-like peptide-1
     (GLP-1) in subjects with NIDDM. Diabetologia. 1997;
     40(2):205-211.

18. Buteau J. GLP-1 receptor signaling: effects on pancreatic
      beta-cell proliferation and survival. 
      Diabetes Metab. 2008;34(suppl 2):S73-S77.

19. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF.
      Insulinotropic hormone glucagon-like peptide-1
      differentiation of human pancreatic islet-derived
      progenitor cells into insulin-producing cells. 
      Endocrinology. 2002;143(8):3152-3161.

20. Drucker DJ. Glucagon-like peptide-1 and the islet beta-
     cell: augmentation of cell proliferation and inhibition of
     apoptosis.Endocrinology. 2003;144(12):5145-5148.

21. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ.
      Glucagon-like peptide-1 receptor signaling modulates
      beta cell apoptosis. J Biol Chem. 2003;278(1):471-478.

22. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like
      peptide-1 inhibits apoptosis of insulin-secreting cells via
      a cyclic 5'-adenosine monophosphate-dependent protein
      kinase A- and a phosphatidylinositol 3-kinase-dependent
      pathway.Endocrinology. 2003;144(4):1444-1455.

23. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like
      peptide 1 inhibits cell apoptosis and improves
      glucose responsiveness of freshly isolated human
      islets. Endocrinology. 2003;144(12):5149-5158.

24. Toft-Nielsen MB, Damholt MB, Madsbad S, et al.
     Determinants of the impaired secretion of glucagon-
     like peptide-1 in type-2 diabetic patients. J Clin
     Endocrinol Metab. 2001;86(8):3717-3723.